What it's sold for

Weight loss
Blood sugar control
Metabolic health

What has actually been tested

Obesity
Type 2 Diabetes
Overweight
Healthy
Adolescents With Obesity
Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Alcohol Use Disorder
Coronary Heart Disease

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Weight loss

Not listed Blood sugar control

Studied Metabolic health

Every trial on record

Every registered human study we can find for Mazdutide. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial ID	Title	Condition	Phase	Status	Enrolled
NCT07517042	ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management	Obesity, Weight Control	Not phased	Recruiting now	420
NCT07135141	Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity	Severe Obesity	Not phased	Not yet recruiting	256
NCT07713992	Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide	Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus	Not phased	Not yet recruiting	72
NCT06931028	A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2	Sleep Apnea, Obstructive	Phase 3	Recruiting now	260
NCT07718126	Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)	Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis	Phase 3	Not yet recruiting	60
NCT06143956	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	Obesity, Overweight	Phase 2	Recruiting now	1481
NCT07417306	A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor	Type 2 Diabetes	Phase 3	Not yet recruiting	912
NCT07083154	GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)	Dementia, Mild, Mild Cognitive Impairment	Phase 3	Recruiting now	420
NCT06937749	A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	Metabolic Dysfunction-associated Steatohepatitis (MASH)	Phase 2	Recruiting now	165
NCT07469800	Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity	Overweight, Obesity	Phase 3	Recruiting now	336
NCT07633639	GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity	Obesity	Not phased	Recruiting now	200
NCT07657676	Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity	Obesity & Overweight, Coronary Heart Disease	Phase 4	Not yet recruiting	116
NCT06519656	Efficacy of Mazdutide for Treating PCOS	Polycystic Ovary Syndrome	Phase 2	Recruiting now	50
NCT07255209	A Study of IBI362 in Chinese Adolescents With Obesity or Overweight	Adolescents With Obesity or Overweight With Weight-Related Comorbidities	Phase 3	Recruiting now	180
NCT07654062	Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)	Prediabetes, Impaired Fasting Glucose	Phase 4	Not yet recruiting	150
NCT06862908	A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity	Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)	Phase 2	Recruiting now	141
NCT06124807	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight	Obesity, Overweight and Obesity	Phase 2	Completed	179
NCT04904913	A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects	Overweight/ Obesity	Phase 2	Completed	328
NCT05607680	A Study of IBI362 in Participants With Obesity or Overweight	Obesity Or Overweight	Phase 3	Completed	610
NCT02972645	A Study of LY3305677 in Healthy Participants	Healthy	Phase 1	Completed	66
NCT04773977	Clinical Study of IBI362 in Healthy Chinese Male Subjects	Overweight/Obesity	Phase 1	Completed	24
NCT06817356	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder	Alcohol Use Disorder	Phase 2	Completed	308
NCT06536023	This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity	Adolescents With Obesity	Phase 1	Completed	36
NCT05623839	A Study of LY3305677 in Participants With Obesity Or Overweight	Overweight, Obesity	Phase 1	Completed	32
NCT05606913	A Study of IBI362 in Participants With Type 2 Diabetes	Type 2 Diabetes	Phase 3	Completed	731
NCT03928379	A Study of LY3305677 in Participants With Type 2 Diabetes	Diabetes Mellitus, Type 2	Phase 1	Completed	24
NCT05815680	A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects	Overweight Subjects, Obese Subjects	Phase 1	Completed	48
NCT04440345	Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects	Overweight or Obesity	Phase 2	Completed	60
NCT05628311	A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise	Type 2 Diabetes	Phase 3	Completed	319
NCT06184568	A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity	Type 2 Diabetes, Obesity	Phase 3	Completed	349
NCT04466904	Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM	Type 2 Diabetes	Phase 2	Completed	42
NCT03325387	A Study of Multiple Doses of LY3305677 in Healthy Participants	Healthy	Phase 1	Completed	56
NCT05793450	Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment	Renal Impairment	Phase 1	Completed	20
NCT04965506	A Study of IBI362 in Chinese Patients With Type 2 Diabetes	Type 2 Diabetes	Phase 2	Completed	252
NCT07000955	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity	Obesity	Phase 2	Running, closed to new participants	98
NCT06164873	A Study of IBI362 9 mg in Chinese Adults With Obesity	Obesity	Phase 3	Running, closed to new participants	462
NCT06884293	A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）	Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)	Phase 3	Running, closed to new participants	479

—Read this

A trial count is not a verdict

These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Why sources disagree on this number

Different sites publish different counts for Mazdutide because they are answering different questions. Here is every way of counting the same set of studies, so you can see which rule produces which number.

Registered human trials the number we publish

Interventional studies in people, listed on ClinicalTrials.gov, at any status.

Completed

Registered trials whose status is "completed".

Still running

Recruiting, not yet recruiting, or active.

Stopped early

Terminated, withdrawn, or suspended.

With a stated phase

Registered trials tagged Phase 1-4.

100+ participants

Registered trials enrolling at least 100 people.

Observational studies

Studies that watch rather than intervene.

You may see a lower number than 37.

Sources that count only completed studies get 18. We count registered trials at any status, because a trial that is recruiting is still a real trial and is the thing most likely to change this page. Neither number is wrong; they answer different questions.

Some counts only include trials with a stated phase.

That yields 33 rather than 37. Not every registered study is tagged with a phase — some are marked "not applicable" — so phase-only counts run lower.

Which number should you use?

For "how much human evidence exists", 37 is the honest answer, with the caveat that 18 have actually finished. Every trial is listed on this page with its ID — if you disagree with how we count, you can recount it yourself in about a minute.

Common questions about Mazdutide

How many human trials does Mazdutide have?

37. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Mazdutide FDA approved?

No. Mazdutide is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Mazdutide actually being tested for?

Registered studies cover: obesity, weight control, severe obesity. Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.